Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear ß-catenin in inflammatory bowel disease-related oncogenesis

Peptides

Volumn 28, Issue 10, 2007, Pages 2030-2035

  Bossard, Céline ^a,b,c   Souazé, Frédérique ^a   Jarry, Anne ^a,b   Bezieau, Stéphane ^b   Mosnier, Jean François ^a,b,c   Forgez, Patricia ^a   Laboisse, Christian L ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

APC catenin pathway; Colorectal oncogenesis; Inflammatory bowel disease; Neurotensin (NT); Neurotensin high affinity receptor 1 (NTS1)

Indexed keywords

BETA CATENIN; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; NUCLEAR BETA CATENIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DYSPLASIA; ENTERITIS; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; COLONIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; LIGANDS; NEUROTENSIN; RECEPTORS, NEUROTENSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34548665706     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.06.030     Document Type: Article

References (21)

1. Aust D.E., Terdiman J.P., Willenbucher R.F., Chew K., Ferrell L., Florendo C., et al. Altered distribution of beta-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod Pathol 14 (2001) 29-39
2. Bernstein C.N., Blanchard J.F., Kliewer E., and Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91 (2001) 854-862
3. Branka J.E., Vallette G., Jarry A., Bou-Hanna C., Lemarre P., Van P.N., et al. Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology 112 (1997) 1887-1894
4. Brun P., Mastrotto C., Beggiao E., Stefani A., Barzon L., Sturniolo G.C., et al. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 288 (2005) G621-G629
5. Carraway R.E., and Plona A.M. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides 27 (2006) 2445-2460
6. Castagliuolo I., Wang C.C., Valenick L., Pasha A., Nikulasson S., Carraway R.E., et al. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest 103 (1999) 843-849
7. Evers B.M. Neurotensin and growth of normal and neoplastic tissues. Peptides 27 (2006) 2424-2433
8. Ferris C.F., and Neurotensin. In: Makhlouf G.M. (Ed). Handbook of physiology. The gastrointestinal system (1989), Neural and Endocrinebiology, Bethesda, MD 559-586
9. Geboes K., Riddell R., Ost A., Jensfelt B., Persson T., and Lofberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 47 (2000) 404-409
10. Maoret J.J., Pospai D., Rouyer-Fessard C., Couvineau A., Laboisse C., Voisin T., et al. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun 203 (1994) 465-471
11. Maoret J.J., Anini Y., Rouyer-Fessard C., Gully D., and Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 80 (1999) 448-454
12. Moody T.W., Chiles J., Casibang M., Moody E., Chan D., and Davis T.P. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 22 (2001) 109-115
13. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275 (1997) 1787-1790
14. Riddell R.H., Goldman H., Ransohoff D.F., Appelman H.D., Fenoglio C.M., Haggitt R.C., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14 (1983) 931-968
15. Riegler M., Castagliuolo I., Wang C., Wlk M., Sogukoglu T., Wenzl E., et al. Neurotensin stimulates Cl(-) secretion in human colonic mucosa In vitro: role of adenosine. Gastroenterology 119 (2000) 348-357
16. Souaze F., Rostene W., and Forgez P. Neurotensin agonist induces differential regulation of neurotensin receptor mRNA. Identification of distinct transcriptional and post-transcriptional mechanisms. J Biol Chem 272 (1997) 10087-10094
17. Souaze F., Viardot-Foucault V., Roullet N., Toy-Miou-Leong M., Gompel A., Bruyneel E., et al. Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis 27 (2006) 708-716
18. Souaze F., Dupouy S., Viardot-Foucault V., Bruyneel E., Attoub S., Gespach C., et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res 66 (2006) 6243-6249
19. Souaze F., and Forgez P. Molecular and cellular regulation of neurotensin receptor under acute and chronic agonist stimulation. Peptides 27 (2006) 2493-2501
20. Tumours of the digestive system. In: Hamilton SR, Aaltonen LA, editors. World Health Organization Classification of Tumours. Pathology and Genetics;2000:103-19.
21. Zhao D., and Pothoulakis C. Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation. Peptides 27 (2006) 2434-2444